Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.52 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6520302 | 1.00 | CYP1A2 (0.58) | CYP1A2SIGMAR1METAP1CHRM5ADRA2C | |
| SCHEMBL6516932 | 1.00 | CYP1A2 (0.58) | CYP1A2SIGMAR1METAP1CHRM5ADRA2C | |
| SCHEMBL1524766 | 1.00 | CYP1A2 (0.58) | CYP1A2SIGMAR1METAP1CHRM5ADRA2C | |
| SCHEMBL6077957 | 1.00 | CYP1A2 (0.58) | CYP1A2SIGMAR1METAP1CHRM5ADRA2C | |
| SCHEMBL6524230 | 1.00 | CYP1A2 (0.58) | CYP1A2SIGMAR1METAP1CHRM5ADRA2C | |
| SCHEMBL6518887 | 1.00 | CYP1A2 (0.58) | CYP1A2SIGMAR1METAP1CHRM5ADRA2C | |
| SCHEMBL5617552 | 1.00 | CYP1A2 (0.58) | CYP1A2SIGMAR1METAP1CHRM5ADRA2C | |
| SCHEMBL11407095 | 1.00 | CYP1A2 (0.58) | CYP1A2SIGMAR1METAP1CHRM5ADRA2C | |
| SCHEMBL2573209 | 1.00 | CYP1A2 (0.58) | CYP1A2SIGMAR1METAP1CHRM5ADRA2C | |
| SCHEMBL2575331 | 1.00 | CYP1A2 (0.58) | CYP1A2SIGMAR1METAP1CHRM5ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024104273-A1 | POLYCARBONATE POLYDIMETHYLSILOXANE TYPE POLYURETHANE UREA AND PREPARATION METHOD THEREFOR | 北京新尖科技有限公司 | 2024-05-23 | — | — | WO | claimed |
| US-11814563-B2 | Bioreachable chiral dopants for liquid crystal applications | ZYMERGEN INC. (US) | 2023-11-14 | — | — | US | claimed |
| US-20230203378-A1 | FORMULATIONS OF BIOREACHABLE DOPANTS FOR LIQUID CRYSTALS | KENT STATE UNIVERSITY | 2023-06-29 | — | — | US | claimed |
| CN-115490827-A | Polycarbonate polydimethylsiloxane type polyurethane urea and preparation method thereof | 北京新尖科技有限公司 | 2022-12-20 | — | — | CN | claimed |
| US-20220025267-A1 | BIOREACHABLE CHIRAL DOPANTS FOR LIQUID CRYSTAL APPLICATIONS | ZYMERGEN ACQUISITION SUB, INC. | 2022-01-27 | — | — | US | claimed |
| EP-3891252-A2 | BIOREACHABLE CHIRAL DOPANTS FOR LIQUID CRYSTAL APPLICATIONS | Zymergen Inc. (US) | 2021-10-13 | — | — | EP | claimed |
| CN-113454187-A | Biologically available chiral dopants for liquid crystal applications | 齐默尔根公司 | 2021-09-28 | — | — | CN | claimed |
| US-11078432-B2 | Hydrodeoxygenation of lignin to hydrocarbons using bimetallic catalysts | WASHINGTON STATE UNIVERSITY (US) | 2021-08-03 | — | — | US | claimed |
| CN-113122059-A | Preparation method of ink and quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| US-20200377803-A1 | HYDRODEOXYGENATION OF LIGNIN TO HYDROCARBONS USING BIMETALLIC CATALYSTS | WASHINGTON STATE UNIVERSITY | 2020-12-03 | — | — | US | claimed |
| US-5139698-A | Achiral liquid crystal compound with doping component | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1992-08-18 | — | — | US | claimed |
| EP-0208541-B1 | LUBRICANT COMPOSITIONS | NIPPON OIL CO. LTD. (JP) | 1991-12-04 | — | — | EP | claimed |
| US-5043093-A | Liquid crystals | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1991-08-27 | — | — | US | claimed |
| EP-0408995-A2 | Liquid crystal medium with limited temperature-dependence of the d/p coefficient | MERCK PATENT GmbH (DE) | 1991-01-23 | — | — | EP | claimed |
| US-4724097-A | LIQUID CRYSTALS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1988-02-09 | — | — | US | claimed |
| US-4702562-A | MIXTURE-FOR MULTIPLEXING | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1987-10-27 | — | — | US | claimed |
| EP-0125563-B1 | BICYCLOHEXYL ETHANES | MERCK PATENT GmbH (DE) | 1987-05-27 | — | — | EP | claimed |
| EP-0208541-A2 | Lubricant compositions | NIPPON OIL CO. LTD. (JP) | 1987-01-14 | — | — | EP | claimed |
| US-4606845-A | DIELECTRICS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1986-08-19 | — | — | US | claimed |
| EP-0125563-A2 | Bicyclohexyl ethanes | MERCK PATENT GmbH (DE) | 1984-11-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078432-B2 | Hydrodeoxygenation of lignin to hydrocarbons using bimetallic catalysts | HMOX2, HMOX1, DUOX1 | CYP1A2 636/4885SIGMAR1 2426/4885METAP1 3827/4885 |
| US-20200377803-A1 | HYDRODEOXYGENATION OF LIGNIN TO HYDROCARBONS USING BIMETALLIC CATALYSTS | HMOX2, HMOX1, DUOX1 | CYP1A2 636/4885SIGMAR1 2426/4885METAP1 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.